For the first time in the United States, a clinical trial is underway that’s evaluating a device designed to treat diastolic heart failure. The first patient enrolled in the randomized, blinded study is being treated at The Ohio State University Wexner Medical Center.

Philips announced that new clinical trial data demonstrates the benefits of its intravascular ultrasound (IVUS) technology in the diagnosis of iliofemoral venous obstruction i.e. narrowed or blocked leg veins.

February 26, 2016 — For the first time, scientists at The Ohio State University have engineered new calcium receptors ...

Biotronik announced that its Itrevia 7 HF-T cardiac resynchronization therapy defibrillator (CRT-D) has now been approved for full-body magnetic resonance imaging (MRI) scanning in Japan.

ArtVentive Medical Group Inc. announced enrollment in the ongoing ArtVentive EOS Endoluminal Occlusion System, OCCLUDE post-market surveillance study.

Using clot-busting drugs to clear blood from the brain’s ventricles may be the first effective strategy to decrease mortality for a type of catastrophic bleeding stroke, according to new phase-3 clinical trial results.

The U.S. Food and Drug Administration (FDA) approved an expanded indication trial for low-risk surgical patients using Medtronic’s CoreValve Evolut R System transcatheter aortic valve replacement (TAVR) system. Patients with aortic stenosis, who are at a low surgical mortality risk as determined by a heart team, will be enrolled in the trial.

TherOx Inc. announced the first patient has been enrolled in an Investigational Device Exemption (IDE) confirmatory study of its second-generation system that delivers supersaturated oxygen (SSO2) therapy for reduction of infarct size after an acute myocardial infarction (AMI). This study is being conducted to support a premarket approval submission to the U.S. Food and Drug Administration (FDA).